in clinical development for various indications, and a pipeline of other drug candidates within oncology, virology, and anti-inflammatory diseases. Its products primarily include Elacytarabine, which is in the Phase II clinical trials for various solid tumor indications, as well as in Phase I/II clinical trials for the treatment of blood cancers, including leukemia; Intravenous CP-4126, a multicentre trial open to patients with any type of solid tumours that is in Phase I clinical trials; Oral CP-4126, an analogue of gemcitabine, which is Phase I clinical trial; and CP-4200, an epigenetic modulator that is in preclinical stage for the treatment of hematological malignancies, such as MDS and leukemia. The company�s products also include CP-4010, an analogue of acyclovir that is in the Phase I clinical trial for the treatment of herpes labialis and herpes genitalis; and CP-4018, an analogue of gancyclovir, which is in the preclinical stage. In addition, its products comprise CP-4033, CP-4112, and CP-4114 that are the analogues of ribavirin, betamethason, and prednisolon respectively. The company has a collaboration agreement with Mount Sinai School of Medicine for the design and testing of new LVT based drug candidates for the treatment of cancer and haematological malignancies. Clavis Pharma ASA was founded in 2001 and is headquartered in Oslo, Norway.